Joint Clinical Research Centre

Curadev Pharma announces the formation of its Clinical Advisory Group

Retrieved on: 
Friday, December 23, 2022
Hospital, Patient, Dana–Farber Cancer Institute, ESMO, US, Joint Clinical Research Centre, CAG, Squamous cell carcinoma, Immune system, Tata Memorial Centre, Patent, University, NCCN, Society, Image, Precision medicine, CSO, Health, Lung cancer, FIH, ACTREC, DNA repair, DNA, Therapy, Cancer, Haematopoietic system, Medicine, Research, Pharmaceutical industry, Medical imaging

Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers.

Key Points: 
  • Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers.
  • Dr. Arjun Surya, CEO and CSO of Curadev said that, "We are honored to work with such an esteemed group of accomplished clinician researchers.
  • The expertise of these KOLs in the early stages of clinical development will be instrumental in unlocking the promise of CRD3874".
  • His areas of interest are hemato-oncology and bone marrow transplantation and he is a founder member of Indian Myeloma Group (IMAGe).

Caring Cross and the Global Gene Therapy Initiative Deliver Presentations at the "Advanced Therapy for Sickle Cell Disease in Africa" Meeting at Muhimbili University of Health and Allied Sciences

Retrieved on: 
Tuesday, February 8, 2022
Thalassemia, Global Genes, SCD, Cell, Muhimbili University of Health and Allied Sciences, Ministry of Education (Malaysia), Aga Khan Hospital, Dar es Salaam, Gene, Joint Clinical Research Centre, HIV, Sickle cell disease, World, Bill & Melinda Gates Foundation, MUHAS, Program, Patient, JCRC, Method, Fred Hutchinson Cancer Research Center, Physician, Association, Dropull, World Health Organization, Haematopoietic system, Associate, Pharmaceutical industry, Medical device

"Caring Cross ishonored to participate in this important meeting and support the mission to accelerate the introduction of gene therapies for Sickle Cell Disease to Africa."

Key Points: 
  • "Caring Cross ishonored to participate in this important meeting and support the mission to accelerate the introduction of gene therapies for Sickle Cell Disease to Africa."
  • Dr. Adair commented: "The Global Gene Therapy Initiative is pleased to participate in this important meeting and support the advancement of curative interventions for Sickle Cell Disease.
  • Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability and applicability of CAR-T technology and stem cell gene therapy.
  • A stem cell gene therapy for Sickle Cell Disease and Beta-Thalassemia is also in development.

Caring Cross to Lend Insight to "Democratization of Access to Transformative Cell and Gene Therapies" Panel at Meeting on the Mesa 2021

Retrieved on: 
Wednesday, October 13, 2021
Fred Hutchinson Cancer Research Center, Program, Method, Hemoglobinopathy, Education, Thalassemia, JCRC, Sickle cell disease, HIV, Patient, LMIC, Joint Clinical Research Centre, Global Genes, Bill & Melinda Gates Foundation, Pharmaceutical industry, Vaccine, Medical device

"However, the current price of such therapies limits patient access, particularly in underserved and less-developed communities around the world.

Key Points: 
  • "However, the current price of such therapies limits patient access, particularly in underserved and less-developed communities around the world.
  • Caring Cross is a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and ensuring access to cures for all patients, everywhere.
  • Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability and applicability of CAR-T technology and stem cell gene therapy.
  • A stem cell gene therapy for Sickle Cell Disease and Beta-Thalassemia is also in development.